Cereno Scientific publishes prospectus related to its rights issue
Cereno Scientific AB (”Cereno Scientific” or "the Company") has established a prospectus related to the Company´s rights issue of B-shares (the ”Rights Issue”), which was made public April 12, 2019. The prospectus has now been approved by the Swedish Financial Supervisory Authority (Sw: Finansinspektionen) and is now available at the Company’s Swedish website, www.cerenoscientific.com and will be published at Mangold Fondkommission AB’s website, www.mangold.se, Spotlight Stock Market’s website, www.spotlightstockmarket.com as well as the Swedish Financial Supervisory Authority´s website, www.fi.se.
N.B. The English text is an in-house translation of the original Swedish text. Should there be any disparities between the Swedish and the English text, the Swedish text shall prevail.
Application forms and other information about the Rights Issue will be available on the Company's website, www.cerenoscientific.com as well as Mangold Fondkommission AB’s website, www.mangold.se from the May 23, 2019. The record date in order to receive subscription rights is May 21, 2019. The subscription period will be from May 23, 2019 up and until June 7, 2019.
Mangold Fondkommission AB is acting as financial adviser to the Company in the Rights Issue. Advokatfirman MAQS is acting as the legal adviser to the Company.
About Cereno Scientific AB
Cereno Scientific is developing novel preventive medicine to treat thrombosis-related disease, based on the body’s own intelligent clot-busting system. Cardiovascular disease is currently the leading cause of death worldwide. Current therapies are connected to an increased risk of bleeding and, as a result, low effectiveness due to lower dosing levels. In turn, this leads to a high risk of new blood clots. Cereno Scientific’s drug candidate, CS1, is expected to provide a possibility for an effective prevention of thrombosis and a lower risk for serious bleeding complications than with current blood thinning therapies. CS1 is an innovative controlled release formulation of a known compound, and as such is expected to have a relatively short development time. In parallel with the development of CS1, Cereno Scientific develops CS014, a preclinical phase compound with promising and innovative characteristics in cardiovascular diseases. The Gothenburg-based company is located in AstraZeneca’s BioVenture Hub and is supported by GU Ventures. Cereno Scientific’s B share has been listed on Spotlight Stock market since June 2016 with the ticker CRNO B, ISIN SE0008241558.
This press release is not an offer to subscribe for shares in Cereno Scientific and investors should not subscribe or acquire any securities. Invitation to concerned persons to subscribe for shares in Cereno Scientific will only be made through the prospectus that Cereno Scientific is expected to publish on May 20, 2019.
This press release shall not, directly or indirectly, be released, published or distributed in or to the United States, Australia Japan, Canada, New Zealand, Hong Kong, South Africa or other country where such action as a whole or in part is subject to legal restrictions.
Neither subscription rights, shares subscribed for ("BTA") or newly issued shares have been recommended or approved by any US federal or state securities authority or regulatory authority. No subscription rights, BTA or newly issued shares have been registered or will be registered under the United States Securities Act of 1933, as applicable, or in accordance with applicable laws in the United States, Australia, Hong Kong, Japan, Canada, New Zealand, Switzerland, Singapore, South Africa or in any other country where the Rights Issue or distribution of the press release is in violation of applicable laws or regulations or presupposes that a further prospectus is established, registered or that any other measure is undertaken beyond that required by Swedish law.
There is no intention to register any portion of the offer in the United States and the securities issued in the Rights Issue will not be offered to the public in the United States.
This press release may contain certain forward-looking information that reflects Cereno Scientific's current views on future events as well as financial and operational development. Words that are "intended", "come", "judged", "expected", "can", "plan", "appreciate" and other expressions that imply indications or predictions about future developments or trends, constitute forward-looking information. Forward-looking information is inherently associated with both known and unknown risks and uncertainties because it depends on future events and circumstances. Forward-looking information does not constitute a guarantee of future performance or development and actual outcomes may differ substantially from what is stated in forward-looking information. This information, the opinions and the forward-looking statements contained in this press release are valid only on this date and may be amended without notice. Cereno Scientific makes no representations about publishing updates or revisions of forward-looking information, future events or similar circumstances other than the applicable law.